Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 18/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 18/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 18/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4027149 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL29684788 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4027145 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6178537 | 0.95 | PDE4A (0.90) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6178526 | 0.95 | PDE4A (0.90) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4030287 | 0.90 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4031387 | 0.90 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4030289 | 0.90 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4031380 | 0.90 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4031390 | 0.90 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277603-A1 | VEILLONELLA PARVULA STRAIN AS AN ORAL THERAPY FOR NEUROINFLAMMATORY DISEASES | EVELO BIOSCIENCES, INC. | 2023-09-07 | — | — | US | claimed |
| US-20230256032-A1 | PREVOTELLA HISTICOLA STRAIN C AS AN ORAL THERAPY FOR INFLAMMATORY DISEASES | EVELO BIOSCIENCES, INC. | 2023-08-17 | — | — | US | claimed |
| CN-116322656-A | Oral treatment of Prevotella denticola strain C as an inflammatory disease | 伊夫罗生物科学公司 | 2023-06-23 | — | — | CN | claimed |
| CN-116249540-A | Oral therapy of veillonella parvula strains as neuroinflammatory disorders | 伊夫罗生物科学公司 | 2023-06-09 | — | — | CN | claimed |
| EP-4185307-A1 | VEILLONELLA PARVULA STRAIN AS AN ORAL THERAPY FOR NEUROINFLAMMATORY DISEASES | Evelo Biosciences, Inc. (US) | 2023-05-31 | — | — | EP | claimed |
| EP-4185276-A1 | PREVOTELLA HISTICOLA STRAIN C AS AN ORAL THERAPY FOR INFLAMMATORY DISEASES | Evelo Biosciences, Inc. (US) | 2023-05-31 | — | — | EP | claimed |
| WO-2022178209-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES AND DISORDERS USING CHRISTENSENELLACEAE BACTERIA | EVELO BIOSCIENCES, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| US-20220118030-A1 | BACTERIAL MEMBRANE PREPARATIONS | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-04-21 | — | — | US | claimed |
| US-11266700-B2 | Compositions and methods for treating immune disorders using immune modulating Lactococcus bacteria strains | EVELO BIOSCIENCES, INC. (US) | 2022-03-08 | — | — | US | claimed |
| WO-2022020326-A1 | VEILLONELLA PARVULA STRAIN AS AN ORAL THERAPY FOR NEUROINFLAMMATORY DISEASES | EVELO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | claimed |
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | MERCK FROSST CANADA LTD. (CA) | 2006-02-23 | — | — | US | claimed |
| EP-1592419-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | Merck Frosst Canada & Co. (CA) | 2005-11-09 | — | — | EP | claimed |
| EP-1562588-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004087157-A2 | COMBINATION OF GH SECRETAGOGUES AND PDE4 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2004-10-14 | — | — | WO | claimed |
| WO-2004047836-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | claimed |
| WO-2004045508-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-06-03 | — | — | WO | claimed |
| EP-1244628-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | claimed |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-08-01 | — | — | US | claimed |
| US-6410563-B1 | RESPIRATORY SYSTEM DISORDERS; ANTIARTHRITIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-06-25 | — | — | US | claimed |
| WO-2001046151-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.